Vaccination induces HIV broadly neutralizing antibody precursors in humans.
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial…
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into B cells that are able to produce broadly neutralizing antibodies. CD4 T cell help will be critical for the development of such high-affinity neutralizing antibody responses. Thus, we assessed the induction and epitope specificities of the vaccine-specific T cells…
Ozette’s AI in the battle against COVID-19.
In-depth immune profiling reveals a T regulatory signature that correlates with COVID-19 disease severity, an important finding as Treg cells are potential targets for treatment strategies and fighting severe disease.
Going beneath the surface of skin cancer.
We investigated our AI’s ability to predict treatment response to PD1 inhibiting immunotherapy in Merkel cell carcinoma and melanoma. We benchmarked our algorithmic approach against conventional analysis.
Ozette’s AI aids advancement of cancer drug development.
Ozette’s technology, in conjunction with other new methods, reveal a distinct T cell population that suppresses immune effectiveness in the tumor microenvironment and helps inform drug development in immuno-oncology.